Editorial: Antiviral therapy for acute-on-chronic liver failure in chronic hepatitis B: Is it too late?

Digestive Diseases and Sciences

Volumn 55, Issue 8, 2010, Pages 2126-2128

  Chan, Henry Lik Yuen ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; TENOFOVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CANCER RISK; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; PRIORITY JOURNAL; SURVIVAL; THROMBOCYTE COUNT; TREATMENT OUTCOME; LIVER TRANSPLANTATION; NOTE;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION;

EID: 77954424709     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1266-6     Document Type: Editorial

References (20)

1. AS Lok BJ McMahon 2007 Chronic hepatitis B Hepatology 45 507 539 10.1002/hep.21513 1:CAS:528:DC%2BD2sXisVKns7o%3D 17256718 (Pubitemid 46374607)
2. European Association for the Study of the Liver 2009 EASL clinical practice guidelines: management of chronic hepatitis B J Hepatol 50 227 242 10.1016/j.jhep.2008.10.001 1:STN:280:DC%2BD1M%2FntlOjtA%3D%3D 19054588
3. YF Liaw N Leung JH Kao et al. 2008 Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 263 283 10.1007/s12072-008-9080-3 19669255
4. CJ Chen HI Yang J Su et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 10.1001/jama.295.1.65 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D 16391218 (Pubitemid 43042691)
5. HL Chan CH Tse F Mo et al. 2008 High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma J Clin Oncol 26 177 182 10.1200/JCO.2007.13.2043 1:CAS:528:DC%2BD1cXitVWitr8%3D 18182659
6. YF Liaw JJ Sung WC Chow et al. 2004 Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 1521 1531 10.1056/NEJMoa033364 1:CAS:528:DC%2BD2cXot1Kls7w%3D 15470215 (Pubitemid 39315319)
7. RJ Fontana ASF Lok 2000 Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when J Heptol 33 329 332 10.1016/S0168-8278(00)80376-1 1:CAS:528:DC%2BD3cXlvVyksrw%3D (Pubitemid 30485239)
8. AY Hui HL Chan NW Leung LC Hung FK Chan JJ Sung 2002 Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation J Clin Gastroenterol 34 569 572 10.1097/00004836-200205000-00018 11960072 (Pubitemid 34429420)
9. VW Wong HL Chan 2009 Severe acute exacerbation of chronic hepatitis B-a unique presentation of a common disease J Gastroenterol Hepatol 24 1179 1186 10.1111/j.1440-1746.2009.05924.x 1:CAS:528:DC%2BD1MXht1Wqt7fL 19682192
10. HL Chan SW Tsang Y Hui NW Leung FK Chan JJ Sung 2002 The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice J Viral Hepat 9 424 428 10.1046/j.1365-2893.2002.00385.x 12431204 (Pubitemid 35373763)
11. RN Chien CH Lin YF Liaw 2003 The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B J Hepatol 38 322 327 10.1016/S0168-8278(02)00419-1 1:CAS:528:DC%2BD3sXhtVemtbk%3D 12586298 (Pubitemid 36286545)
12. SW Tsang HL Chan NW Leung et al. 2001 Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection Aliment Pharmacol Ther 15 1737 1744 10.1046/j.1365-2036.2001.01107.x 1:CAS:528:DC%2BD3MXosVWqt7s%3D 11683687 (Pubitemid 33001137)
13. MF Yuen E Sablon CK Hui et al. 2003 Prognostic factors in severe exacerbation of chronic hepatitis B Clin Infect Dis 36 979 984 10.1086/374226 12684909 (Pubitemid 36513281)
14. Cui YL, Yan F, Wang YB et al. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection associated with acute-on-chronic liver failure. Dig Dis Sci. 2010 (in press).
15. HL Tillmann J Hadem L Leifeld et al. 2006 Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience J Viral Hepat 13 256 263 10.1111/j.1365-2893.2005.00695.x 1:STN:280:DC%2BD283gsFOqsQ%3D%3D 16611192
16. HL Chan AM Chim JT Lau AY Hui VW Wong JJ Sung 2006 Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B Am J Gastroenterol 101 1516 1523 10.1111/j.1572-0241.2006.00659.x 16863555 (Pubitemid 43980625)
17. VW Wong AM Chim GL Wong JJ Sung HL Chan 2007 Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B Liver Transpl 13 1228 1235 10.1002/lt.21222 17763399 (Pubitemid 47457049)
18. VW Wong GL Wong SW Tsang et al. 2008 Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B Antivir Ther 13 571 579 18672536
19. HL Chan VW Wong AY Hui et al. 2006 Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B Antivir Ther 11 465 471 1:CAS:528: DC%2BD28XnsVCksrs%3D 16856620
20. EB Keeffe DT Dieterich SH Han et al. 2008 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update Clin Gastroenterol Hepatol 6 1315 1341 10.1016/j.cgh.2008.08.021 1:CAS:528:DC%2BD1MXhtFSlurk%3D 18845489